PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial

L Liang Zeng Z Zhaohui Ruan H Huan Yan H Haoyue Qin Z Zhen Zeng (School of Chemical Sciences) C Chun Zou Z Zhe Huang W Wenjuan Jiang J Jiacheng Dai S Shidong Xu (Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute) L Lianxi Song Y Yangqian Chen Y Yuda Zhang F Fanxu Zeng S Shiyou Wei S Shanmei Chen L Li Liu Y Yi Xiong Z Zhan Wang J Jun Deng (Center for High Pressure Science and Technology Advanced Research) X Xing Zhang (State Key Laboratory of Elemento-Organic Chemistry, Frontiers Science Center for New Organic Matter, College of Chemistry) Y Yuanze Sun D Dan Yang (Tianjin Key Laboratory of Molecular Drug Research, College of Pharmacy) C Chunhua Zhou H Haiyan Yang Y Yizhi Li L Li Deng (Zhejiang Key Laboratory of Precise Synthesis of Functional Molecules, Department of Chemistry, School of Science and Research Center for Industries of the Future, Westlake University, 600 Dunyu Road, Hangzhou 310030, P. R. China) Q Qinqin Xu C Chao Fang (State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering & Institute of Artificial Intelligence & Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM)) X Xue Chen J Jing Wang (Hunan Cancer Hospital Changsha China) T Ting Li G Gao Zhang H Hui Zhou (Department of Chemistry and Materials) N Nong Yang Y Yongchang Zhang